Le Lézard
Classified in: Health
Subjects: PET, MRR

Companion animal specialty drugs market to grow by USD 4.55 billion from 2023 to 2028; North America to account for 35% of market growth- Technavio


NEW YORK, Nov. 17, 2023 /PRNewswire/ -- The companion animal specialty drugs market size is expected to grow by USD 4.55 billion from 2023 to 2028. In addition, momentum of the market will progress at a CAGR of  6.68% during the forecast period, according to Technavio Research. The market is segmented by distribution channel (veterinary hospitals, pet care clinics, and pharmacy stores), product (Vaccines, Antibiotics, Parasiticides, Feed additives, and Others), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 35% to the growth of the global market during the forecast period. The US, Canada, and Mexico are some of the most important countries that have a major impact on market growth in North America. Furthermore, the adoption rate of pets is on the rise as more and more elderly people seek companionship.

This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report

Company Profile:

Bayer AG, Beaphar Beheer BV, Bimeda Holdings Ltd., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma Group, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Kyoritsuseiyaku Corp., LABORATORIOS CALIER S.A, Mars Inc., Merck and Co. Inc., Neogen Corp., Norbrook Laboratories Ltd., Tianjin ringpu bio-technology Co. Ltd., Vetoquinol SA, Virbac Group, Zenex Animal Health India Private Ltd., Zoetis Inc., and Orion Corp.

   To access more company profiles available with Technavio, buy the report!

Companion Animal Specialty Drugs Market: Segmentation Analysis

The veterinary hospitals segment is estimated to witness significant growth during the forecast period.  For companion animals, this segment provides a wide range of veterinary services. Grooming, vaccination, and flea treatment are some of the fundamental aspects of good pet care.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

Companion Animal Specialty Drugs Market: Driver & Trend:

Key Drivers- 

One of the key factors driving the companion animal specialty drugs is the rise in the aging companion animal population. There is an upsurge in the elderly companion animal population across the globe as the owners of companion animals wish to provide proper nutrition to control aging effects. Also, the requirement for minerals and vitamins to support growing dogs is adequate for senior dogs. 

A key factor shaping market growth is the rising obesity in companion animals. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.

Related Reports:

The erectile dysfunction (ED) drugs market is estimated to grow by USD 1.44 billion at a CAGR of 6.67% between 2023 and 2028. 

The animal biotechnology market is estimated to grow by USD 3.65 billion at a CAGR of 3.01% between 2023 and 2028. 

What are the key data covered in this companion animal specialty drugs market report?

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Distribution Channel

Market Segmentation by Product 

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: